🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesGLP-1 and beta-cell preservation — looking for input Page 2

GLP-1 and beta-cell preservation — looking for input

steph_laguna Thu, Oct 31, 2024 at 6:17 AM 52 replies 2,916 viewsPage 2 of 11
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Oct 31, 2024 at 7:50 AM#6
anders_CPH said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 38% to 21%.

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

14 9pete_manc_UK, anna.melb_AU, mark_tokyo and 11 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Oct 31, 2024 at 8:26 AM#7
steph_laguna said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

My labs after 6 months on glycaemic control: A1C 5.1%, fasting glucose 76 mg/dL, fasting insulin 5 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 6.7% and fasting glucose was 111 mg/dL. The improvement has been dramatic and consistent.

13 8KristenIndy, MarkLI_maint, Dr.PeteFamMed and 10 others
Reply Quote Save Share Report
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
Oct 31, 2024 at 9:02 AM#8
Dr.RaviCardio said:
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include: Biomarker Association…

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)128989282
Insulin (fasting)241285
HOMA-IR4.53.42.01.2
Uric Acid8.16.85.94.9

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.

12 7PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 9 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
Oct 31, 2024 at 9:38 AM#9

Following on from PharmD_Rodriguez — and this may be the naive question:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: Oct 31, 2024 at 10:38 AM
11 6PharmHunterJen, TomTeleRx, DoseLogDan and 8 others
Reply Quote Save Share Report
steph_laguna
Member
234
1,123
Nov 2024
Laguna Beach, CA
Oct 31, 2024 at 12:33 PM#10
Dr.NephBHM_UK said:
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone: Test Baseline Month 3 Month 6 Month 12…

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 6.1 (insulin resistant) → Current = 1.1 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

Last edited: Oct 31, 2024 at 6:33 PM
15 15marco_milano, pam_columbus, nick_SD_fit and 12 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register